尿激酶对急性期脑梗死溶栓治疗的临床价值

摘要

Objective:To investigate the clinical effect of urokinase in the treatment of acute cerebral infarction with cerebral infarction.Method:98 patients with acute cerebral infarction were divided into study group and control group,49 cases in each group.The control group was given routine comprehensive treatment, study group was given urokinase intravenous thrombolysis treatment on the basis of control group,therapeutic effects of two groups were compared.Result:Before treatment,the neurological function defect score of the study group and control group were respectively (20.8±7.5) and (21.1±7.4),the difference was no statistically significant(P<0.05).After treatment,the neurological function defect score in the study group of (7.3±7.2) was significantly better than control group of (13.6±7.3),the difference was statistically significant(P<0.05). The basic cure rate and the total effective rate of study group were 65.3% and 98.0%,the control group of those were respectively 40.8% and 93.9%,the basic cure rate of study group was significantly higher than control group, the difference was statistically significant(P<0.05),but compared the total effective rate of two groups there was no statistically significant difference(P>0.05).The study group had no reinfarction,control group had 6 cases reinfarction, the incidence rate was 12.2%,the incidence of reinfarction in study group was significantly lower than that control group,the difference was statistically significant(P<0.05).Conclusion:Urokinase has good clinical effect in the treatment of acute cerebral infarction with cerebral infarction. It can improve the neurological function of patients, the incidence of adverse reactions is low, the safety is high,it is worthy of further research and promotion.%目的：探讨尿激酶对急性期脑梗死溶栓治疗的临床效果。方法：将98例急性期脑梗死患者分为研究组与对照组，每组各49例。对照组采用常规综合治疗，研究组在对照组治疗的基础上辅以尿激酶静脉溶栓，比较两组的治疗效果。结果：治疗前，研究组与对照组患者神经功能缺损评分分别为（20.8±7.5）分、（21.1±7.4）分，两组比较差异无统计学意义（P>0.05）；治疗后，研究组患者神经功能缺损评分为（7.3±7.2）分，明显优于对照组的（13.6±7.3）分，两组比较差异有统计学意义（P<0.05）；研究组患者基本治愈率、治疗总有效率分别为65.3%、98.0%，对照组分别为40.8%、93.9%，研究组基本治愈率明显高于对照组，两组比较差异有统计学意义（P<0.05），但两组的治疗总有效率比较差异无统计学意义（P>0.05）；研究组未出现再梗死，对照组有6例出现再梗死，再梗死发生率为12.2%，研究组再梗死发生率明显低于对照组，两组比较差异有统计学意义（P<0.05）。结论：尿激酶对急性期脑梗死溶栓治疗有着较好的临床效果，能改善患者神经功能缺损，不良反应发生率低，安全性高，值得在临床上进行深入研究和推广。